Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com
Tucatinib Plus Trastuzumab Induces Durable Tumor Response in HER2+ mCRC
July 2nd 2022Patients with previously treated metastatic HER2-positive colorectal cancer experienced clinically meaningful and durable responses to treatment with tucatinib plus trastuzumab, according to data from the phase 2 MOUNTAINEER trial.
Read More
KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC
July 1st 2022Efforts to unlock treatment modalities targeting KRAS mutations have ebbed and flowed for patients with non–small cell lung as investigators face resistance, intolerable toxicity profiles, and a lack of available binding pockets to guide treatment development.
Read More
A Molecular Revolution Is Underway in Thoracic Oncology
June 20th 2022Targetable alterations including BRAF V600E, EGFR exon 20 insertions, KRAS G12C mutations, MET exon 14 alterations, NTRK and RET rearrangements have taken up recent focus for investigators as data are pushing novel agents through the regulatory processes.
Read More
Adjuvant and Neoadjuvant Treatments Chart New Course in Advanced RCC
June 17th 2022A panel of kidney cancer experts discuss how therapeutic strategies in the neoadjuvant and adjuvant settings are affecting outcomes and how treatment selection in the first line has shifted approaches in the second and later lines of therapy.
Read More
Toolbox Overflows With First-Line Combination Regimens for Advanced RCC
June 14th 2022Mehmet A. Bilen, MD, and a panel of renal cell carcinoma experts discuss the preferred treatment options for patients with intermediate-risk or high-risk advanced renal cell carcinoma and the clinical features that may influence their decisions.
Read More
Tisagenlecleucel Maintains Durable Response at 5 Years in Pediatric/Young Adult Patients With B-ALL
June 13th 2022Long-term follow-up from the phase 2 ELIANA trial, showed that tisagenlecleucel continued to demonstrate durable efficacy in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Read More
Zandelisib Elicits High Response in Relapsed/Refractory Follicular Lymphoma
June 12th 2022Zandelisib, a potent and selective oral PI3Kδ inhibitor, elicited a high overall response rate as a single agent in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to data from the phase 2 TIDAL trial.
Read More
Long-term Treatment With Luspatercept Reduces Transfusion Dependence Associated With β-Thalassemia
June 12th 2022The longest duration of reduction in red blood cell transfusion dependence was reported among patients with β-thalassemia who received continued treatment with luspatercept-aamt in the updated data from the phase 3 BELIEVE trial.
Read More
Time-Limited Venetoclax-Based Combos Improve PFS Outcomes in Treatment-Naïve CLL
June 11th 2022Time-limited targeted therapy with venetoclax plus obinutuzumab with or without ibrutinib demonstrated superior progression-free survival outcomes compared with standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Read More
Asciminib Represents New Standard of Care for Patients With CML in Chronic Phase
June 7th 2022Asciminib continued to demonstrate durable, major molecular responses as well as a tolerable safety profile vs bosutinib suggesting a long-term benefit in adult patients with chronic myelogenous leukemia in chronic phase who have been previously treated with 2 tyrosine kinase inhibitors.
Read More
Dostarlimab Elicits Clinical Complete Response Among All Treated Patients with dMMR Rectal Cancer
June 7th 2022Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.
Read More
Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative breast cancer with endocrine therapy resistance, reducing the risk of disease progression by 34% vs standard chemotherapy, according to results of the phase 3 TROPiCS-02 trial.
Read More
Reshaping the Treatment Landscape for Recurrent/Metastatic Nasopharyngeal Carcinoma
May 26th 2022In the context of checkpoint blockade in nasopharyngeal carcinoma, the results of the phase 3 RATIONALE-309 trial support earlier findings of the role immunotherapy may play for patients in the first line.
Read More
Clinical Benefit With Elacestrant Shines Spotlight on SERDs in ER+/HER2- Breast Cancer
May 23rd 2022A significant improvement in progression-free survival has been reported with the oral selective estrogen receptor degrader elacestrant vs standard of care treatments for patients with estrogen receptor–positive, HER2-negative breast cancer.
Read More
Sacituzumab Govitecan Maintains Clinical Benefit Across HER2 Expressions in TNBC
May 5th 2022Sacituzumab govitecan-hziy maintained clinical benefit in patients with metastatic triple-negative breast cancer regardless of HER2 expression according to a post hoc analysis of the phase 3 ASCENT trial.
Read More
Treatment Optimization Efforts Seek to Overcome Resistance in Advanced CML
April 15th 2022Elias J. Jabbour, MD, and Matthew S. Davids, MD, MMSc, review data on asciminib and ponatinib in the post–second generation TKI setting for chronic myeloid leukemia that were presented at the 2021 ASH Meeting and Exposition.
Read More
SERDs, ESR1 Mutations Dominate Updates in ER-Positive Breast Cancer
March 31st 2022Sara A. Hurvitz, MD, FACP, led a panel of breast cancer experts—Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky, MD, MS—in a review of key data from the 2021 San Antonio Breast Cancer Symposium in ER-positive breast cancer.
Read More